Rabiya Tuma

San Francisco

Oncology and HCP Editorial Lead at HealthCentral Corporation

Oncology and HCP Editorial Lead at Oncology News Central

Oncology and HCP Editorial Lead at Patient Power

Oncology and HCP editorial lead @RemHealthMedia, @OBRtweets and @PatientPower. Science and medical writer, former bench scientist. Tweets are my own. She/her

Featured in: Favicon

remedyhealthmedia.com Favicon

obroncology.com Favicon

patientpower.info Favicon

medscape.com Favicon

oncologynewscentral.com

Articles

FDA Says Company Made Inaccurate Claims About Cancer Drug’s Efficacy on Healthcare Provider Site

2 months ago | oncologynewscentral.com | Youssef Rddad |Rabiya Tuma |Leah Lawrence

On March 21, the U.S. Food and Drug Administration (FDA) sent a letter from its Office of Prescription Drug Promotion to Taiho Oncology, claiming that data posted on the company’s healthcare provider branded website contained “false or misleading” claims about the benefits of futibatinib (Lytgobi) tablets used to treat certain bile duct cancers.
Gynecologic Cancers

May 7, 2024 | oncologynewscentral.com | Leah Lawrence |Youssef Rddad |Rabiya Tuma |Ursula Matulonis
FDA Approves Adjuvant Alectinib for ALK-Positive NSCLC

Apr 18, 2024 | obroncology.com | Rabiya Tuma

On April 18, the U.S. Food and Drug Administration approved alectinib (Alecensa) for the treatment of adults with early-stage anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. The approval is based on results from the ALINA trial, which compared single-agent alectinib with platinum-based chemotherapy.